The two best growth stocks to buy now which are getting ready for next phase of growth after a brief retreat are
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX)
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX) has received FDA approval for its New Drug Application (NDA) for Gozellix®, a next-generation PSMA-PET imaging agent for prostate cancer. Designed for use in men with suspected metastatic or recurrent prostate cancer, it offers improved logistics over existing gallium-based products, including a longer shelf life and extended distribution range. This allows it to reach more imaging centers across the U.S., including areas currently underserved.
Having successfully established Illuccix®, Telix’s first-generation PSMA-PET agent, Gozellix® enhances accessibility to precision imaging and supports more flexible and efficient scanning operations. With PSMA-PET now considered standard care for prostate cancer imaging, Telix is among the top growth stocks aiming for Gozellix® to address the gap in access, especially for the many patients who have yet to benefit from such scans. Full reimbursement and minimal out-of-pocket costs are expected to further support widespread adoption.
Securing FDA approval for Gozellix is also a major turning point for prostate cancer patients, who gain enhanced access to state-of-the art 68Ga PSMA-PET imaging.
WiseTech Global Limited (ASX: WTC)
WiseTech Global Limited (ASX: WTC) delivered a strong first-half FY25 performance, with revenue rising 17% to $381.0 million and EBITDA up 28% to $192.3 million, reflecting improved margins and operational efficiencies. The core CargoWise platform drove growth with a 21% revenue increase, supported by major customer rollouts including Nippon Express and LOGISTEED. EBITDA margin expanded to 50%, supported by pricing strategies and a successful cost-saving program.
While the company revised its full-year revenue outlook to the lower end of its $1.2B–$1.3B range due to delays in the launch of its Container Transport Optimization product, it expects EBITDA margins to reach the higher end of its 50%–51% target. Despite the revenue adjustment, WiseTech is among the best growing companies to invest in as it remains optimistic about its long-term growth, underpinned by high recurring revenue (98%), strong organic performance, and continued innovation through products like CargoWise Next and ComplianceWise. Its leading position in global logistics software and increasing presence among top-tier freight forwarders support a strong future growth outlook.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
